[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 222
1. Martin FT, Kavanagh D, Waldron R: Squamous cell carcinoma of the anal canal. Surgeon; 2009 Aug;7(4):232-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal.
  • Squamous cell carcinoma ofthe anal canal represents 1.5% of all malignancies affectingthe gastrointestinal tract.
  • CLINICAL MANAGEMENT: Historically abdominoperineal resection had been the treatment of choice with local resection reserved for early stage disease.
  • Work by Nigro et al. has revolutionised how we currently manage carcinoma of the anal canal, demonstrating combined modality chemoradiotherapy as an appropriate alternative to surgical resection with the benefit of preserving sphincter function.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736891.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 57
  •  go-up   go-down


2. Yamashita S, Masui T, Katayama M, Sato K, Yoshizawa N, Seo H, Sakahara H: T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences. J Magn Reson Imaging; 2007 Mar;25(3):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences.
  • MATERIALS AND METHODS: Forty patients (stage: pT0, 1; pTis-2, 15; pT3-4, 24) were included in the study.
  • All examinations were performed on a 1.5T magnet with a phased-array coil and the patients were studied in the prone position with per-anal air injection.
  • CONCLUSION: The BH-FRFSE sequence may be the first choice for rectosigmoid T2W imaging in the prone position with per-anal air injection for patients who can hold their breath stably.
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis. Respiration. Sigmoid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326094.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Kopriva I, Persin A: Unsupervised decomposition of low-intensity low-dimensional multi-spectral fluorescent images for tumour demarcation. Med Image Anal; 2009 Jun;13(3):507-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such situation arises when low-dimensional low-intensity multi-spectral image of the tumour in the early stage of development is represented by the SLMM, wherein tumour is spectrally similar to the surrounding tissue.
  • We demonstrate good performance of the method on both computational model and experimental low-intensity red-green-blue fluorescent image of the surface tumour (basal cell carcinoma).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282233.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


Advertisement
4. Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, Yamaguchi H, Egami T, Kitada H, Tanaka M: LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer; 2008;7:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LIM only 4 is overexpressed in late stage pancreas cancer.
  • BACKGROUND: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
  • If so, this could result in a better understanding of tumorigenesis in pancreatic cancer.
  • METHODS: We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
  • RESULTS: 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE).
  • In bulk tissue samples, expression of LMO4 was higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both).
  • These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Analysis of Variance. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. LIM Domain Proteins. Neoplasm Staging. Protein-Serine-Threonine Kinases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 May 19;88(10):1543-8 [12771919.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):93-7 [12629061.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3215-22 [15126362.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):82-8 [15221649.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1887-93 [1923511.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3329-38 [8045262.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jan;12(1):24-31 [7534107.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Pancreas. 1998 Apr;16(3):238-42 [9548661.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):263-9 [9665487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11257-62 [9736723.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 14;1445(1):148-53 [10209267.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] Gene. 2005 Jan 3;344:67-77 [15656974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50:69-72 [16358942.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 19;343(4):1186-90 [16580634.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3878-82 [16804974.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6431-41 [17452977.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):537-41 [18231110.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1623-31 [11073822.001]
  • [Cites] Mamm Genome. 1999 Nov;10(11):1089-94 [10556429.001]
  • [Cites] Pancreatology. 2008;8(6):587-92 [18849640.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7 [11734645.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7849-56 [11751867.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1067-72 [12370756.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):125-36 [14505145.001]
  • (PMID = 19099607.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / LMO4 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2628350
  •  go-up   go-down


5. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY: Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol; 2006 Jun 28;12(24):3911-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
  • AIM: To quantify the circulating DNA in plasma from patients with hepatocellular carcinoma (HCC) and to evaluate its prognostic value.
  • The circulating DNA level was closely associated with tumor size (P = 0.008) and TNM stage (P = 0.040), negatively associated with the 3-year disease-free survival (DFS) (P = 0.017) and overall survival (OS) (P = 0.001).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / pathology. DNA, Neoplasm / blood. Liver Neoplasms / blood. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1047-52 [12631605.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:17-24 [15251934.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Mol Med. 1995 May;1(4):344-65 [8521292.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):578-84 [10080602.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1027-36 [10498656.001]
  • [Cites] Nature. 1953 Apr 25;171(4356):737-8 [13054692.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):59-64 [10585744.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5723-6 [11479206.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):445-54 [11819809.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82 [14571790.001]
  • (PMID = 16804981.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC4087944
  •  go-up   go-down


6. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL: Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation. Cancer Lett; 2010 Apr 1;290(1):49-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
  • Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum.
  • These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Nat Med. 2000 Feb;6(2):164-70 [10655104.001]
  • [Cites] Mediators Inflamm. 2009;2009:535348 [19325914.001]
  • [Cites] Transplantation. 2001 Jun 27;71(12):1777-83 [11455258.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4015-20 [12010802.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Trends Cardiovasc Med. 2002 Nov;12(8):331-8 [12536119.001]
  • [Cites] Immunol Cell Biol. 2003 Apr;81(2):137-43 [12631237.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] J Endotoxin Res. 2003;9(2):119-23 [12803886.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13729-37 [14736878.001]
  • [Cites] BMC Cancer. 2004 Jul 12;4:34 [15248897.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1504-9 [15371880.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):194-5 [629228.001]
  • [Cites] J Clin Pathol. 1979 Jan;32(1):21-5 [429575.001]
  • [Cites] Thromb Haemost. 1981 Aug 28;46(2):500-3 [7302888.001]
  • [Cites] J Urol. 1982 Jul;128(1):72-4 [7109075.001]
  • [Cites] Am J Med. 1989 Sep 11;87(3B):10S-14S [2552799.001]
  • [Cites] Thromb Haemost. 1996 Dec;76(6):897-901 [8972008.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19393-400 [9235938.001]
  • [Cites] Int J Hematol. 1998 Jul;68(1):67-78 [9713170.001]
  • [Cites] BMC Cancer. 2005;5:73 [16000172.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36541-4 [16115897.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3405-13 [16224818.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):60-5 [16440418.001]
  • [Cites] J Urol. 2006 Apr;175(4):1523-8 [16516040.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Mol Endocrinol. 2007 Jun;21(6):1267-80 [17389748.001]
  • [Cites] Autoimmun Rev. 2007 Nov;7(1):8-11 [17967718.001]
  • [Cites] Electrophoresis. 2007 Dec;28(23):4302-10 [18041032.001]
  • [Cites] Intensive Care Med. 2008 Feb;34(2):361-7 [17940748.001]
  • [Cites] Inflamm Res. 2008 Feb;57(2):45-50 [18288453.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):665-75 [18064633.001]
  • [Cites] Oncology. 2008;75(3-4):127-33 [18791328.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3533-6 [18982159.001]
  • [Cites] J Cell Biochem. 2008 Dec 1;105(5):1279-88 [18821572.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1922-32 [19188446.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1117-23 [10666179.001]
  • (PMID = 19762145.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK075059; United States / NIAID NIH HHS / AI / R01 AI042310-06; United States / NIDDK NIH HHS / DK / DK075059; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NIDDK NIH HHS / DK / DK075059-02; United States / NIDDK NIH HHS / DK / R21 DK075059-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Multiprotein Complexes; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS146096; NLM/ PMC2832085
  •  go-up   go-down


7. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Stage, age and treatment were all significant indicators of survival in uni- and multivariable analysis.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


8. Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS: Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci; 2010;8:58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.
  • BACKGROUND: Diagnosis of ovarian carcinoma is in urgent need for new complementary biomarkers for early stage detection.
  • Proteins that are aberrantly excreted in the urine of cancer patients are excellent biomarker candidates for development of new noninvasive protocol for early diagnosis and screening purposes.
  • In the present study, urine samples from patients with ovarian carcinoma were analysed by two-dimensional gel electrophoresis and the profiles generated were compared to those similarly obtained from age-matched cancer negative women.
  • RESULTS: Significant reduced levels of CD59, kininogen-1 and a 39 kDa fragment of inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), and enhanced excretion of a 19 kDa fragment of albumin, were detected in the urine of patients with ovarian carcinoma compared to the control subjects.
  • CONCLUSION: CD59, kininogen-1 and fragments of ITIH4 and albumin may be used as complementary biomarkers in the development of new noninvasive protocols for diagnosis and screening of ovarian carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083881.001).
  • [ISSN] 1477-5956
  • [Journal-full-title] Proteome science
  • [ISO-abbreviation] Proteome Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2998473
  •  go-up   go-down


9. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


10. Baek WS, Kubba SV: Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary. Gynecol Oncol; 2008 Dec;111(3):544-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 66-year-old female with stage IV ovarian papillary serous cystadenocarcinoma presented with perianal numbness and sphincter dysfunction.
  • On exam she had decreased anal tone with saddle anesthesia.
  • CONCLUSION: Ovarian cancer metastasizng to the cauda equina should be highly suspected based on the clinical presentation alone, even with unremarkable imaging studies.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Meningeal Carcinomatosis / pathology. Ovarian Neoplasms / pathology. Polyradiculopathy / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433846.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F: Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori; 2005 May-Jun;4(3):S31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
  • This paper reports six patients with perianal Crohn's disease (CD), who developed anal cancer in chronic anal fistulas.
  • Tumors have been often diagnosed at an advanced stage and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
  • Patients with perianal CD should undergo a careful surveillance program for ano-rectal carcinoma, including routine biopsy of any suspected lesion.
  • [MeSH-major] Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437885.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Amano M, Yamaguchi M, Takegawa Y, Yamashita T, Terashima M, Furukawa J, Miura Y, Shinohara Y, Iwasaki N, Minami A, Nishimura S: Threshold in stage-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation. Mol Cell Proteomics; 2010 Mar;9(3):523-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Threshold in stage-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation.
  • We demonstrated that processes of dynamic cellular differentiation of mouse embryonic carcinoma cells, P19CL6 and P19C6, and mouse embryonic stem cells into cardiomyocytes or neural cells can be monitored and characterized quantitatively by profiling entire N-glycan structures of total cell glycoproteins.
  • [MeSH-major] Cell Differentiation. Embryonal Carcinoma Stem Cells / chemistry. Embryonic Stem Cells / chemistry. Glycoproteins / analysis. Myocytes, Cardiac / chemistry. Neurons / chemistry. Polysaccharides / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 29;284(5):1098-103 [11414696.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(31):5718-38 [18624353.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):167-73 [12054580.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):363-8 [12417419.001]
  • [Cites] Annu Rev Biochem. 2004;73:491-537 [15189151.001]
  • [Cites] Curr Biol. 2004 Sep 7;14(17):R691-2 [15341754.001]
  • [Cites] Glycoconj J. 2004;21(1-2):41-5 [15467397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5565-9 [281705.001]
  • [Cites] Cell. 1979 Sep;18(1):217-27 [509524.001]
  • [Cites] Nature. 1982 Sep 9;299(5879):165-7 [7110336.001]
  • [Cites] Mol Cell Biol. 1983 Dec;3(12):2280-6 [6656767.001]
  • [Cites] EMBO J. 1983;2(12):2355-61 [6141938.001]
  • [Cites] J Biol Chem. 1989 Jun 5;264(16):9476-84 [2470757.001]
  • [Cites] Glycobiology. 1993 Apr;3(2):97-130 [8490246.001]
  • [Cites] Anal Biochem. 1993 Oct;214(1):70-6 [8250257.001]
  • [Cites] J Biochem. 1993 Sep;114(3):334-8 [8282722.001]
  • [Cites] Cell Struct Funct. 1996 Apr;21(2):101-10 [8790939.001]
  • [Cites] Glycobiology. 1997 Feb;7(1):45-56 [9061364.001]
  • [Cites] Glycobiology. 1999 Aug;9(8):823-31 [10406848.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Dec 17;44(1):91-6 [15599899.001]
  • [Cites] Nat Med. 2005 Feb;11(2):228-32 [15685172.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1656-68 [15789344.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):145-50 [16253979.001]
  • [Cites] Glycobiology. 2006 Mar;16(3):244-57 [16321922.001]
  • [Cites] Cell. 2006 Sep 8;126(5):855-67 [16959566.001]
  • [Cites] Cell Biol Int. 2006 Oct;30(10):800-7 [16877013.001]
  • [Cites] Proteomics. 2006 Oct;6(20):5650-61 [16972299.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2146-57 [16899540.001]
  • [Cites] Cell. 2007 Apr 6;129(1):123-34 [17418791.001]
  • [Cites] Nature. 2007 Apr 26;446(7139):1023-9 [17460663.001]
  • [Cites] Proteomics. 2007 Mar;7(6):910-20 [17370269.001]
  • [Cites] Curr Opin Chem Biol. 2007 Jun;11(3):300-5 [17500024.001]
  • [Cites] J Cell Biochem. 2007 Sep 1;102(1):149-60 [17520663.001]
  • [Cites] Curr Opin Chem Biol. 2007 Aug;11(4):399-404 [17646122.001]
  • [Cites] Curr Opin Chem Biol. 2007 Aug;11(4):373-80 [17681848.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):328-38 [18034457.001]
  • [Cites] Proteomics. 2008 Jan;8(2):264-78 [18203276.001]
  • [Cites] Mol Cell Proteomics. 2008 Feb;7(2):370-7 [17986439.001]
  • [Cites] Anal Chem. 2008 Feb 15;80(4):1094-101 [18205388.001]
  • [Cites] Science. 2002 Jan 4;295(5552):124-7 [11778047.001]
  • (PMID = 20008832.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Polysaccharides
  • [Other-IDs] NLM/ PMC2849713
  •  go-up   go-down


13. Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer; 2010;10:300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
  • BACKGROUND: The development and progression of colorectal cancer has been extensively studied and the genes responsible have been well characterized.
  • METHODS: We examined the paired tumor and normal tissue specimens of 86 CRC patients for the occurrence of aberrations in MCR region of SMAD4 and exon 1 of KRAS by PCR-SSCP and/or PCR-Direct sequencing.
  • CONCLUSION: Our study suggests that SMAD4 gene aberrations are the common event in CRC development but play a differential role in the progression of CRC in higher tumor grade (C+D) and its association with the KRAS mutant status suggest that these two molecules together are responsible for the progression of the tumor to higher/advanced stage.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Mol Cell Biochem. 2009 Dec;332(1-2):51-8 [19513816.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1331-5 [1499084.001]
  • [Cites] Curr Opin Oncol. 1993 Jan;5(1):123-9 [8427884.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):347-9 [8673135.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2578-80 [9205057.001]
  • [Cites] J Pathol. 1998 Jun;185(2):130-8 [9713338.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Oncogene. 1999 Mar 18;18(11):2033-7 [10208426.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):62-8 [15761872.001]
  • [Cites] Am Surg. 2005 Apr;71(4):336-43 [15943410.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5742-50 [16123807.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] Int J Biol Sci. 2010;6(1):1-8 [20087440.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):969-80.e1-3 [19909744.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):235-43 [10712925.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Bioessays. 2001 Mar;23(3):223-32 [11223879.001]
  • [Cites] Ann Agric Environ Med. 2001;8(1):1-5 [11426918.001]
  • [Cites] Genome Biol. 2001;2(8):REVIEWS3010 [11532220.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1293-300 [11583957.001]
  • [Cites] J Cell Biol. 2002 Jan 21;156(2):299-313 [11790801.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):373-80 [12198585.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):387-93 [14506738.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Exp Oncol. 2004 Jun;26(2):98-105 [15273660.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 [3056609.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):339-46 [17390374.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):245-53 [19010789.001]
  • [Cites] Mutat Res. 2009 May 31;676(1-2):5-10 [19486858.001]
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):219-25 [19574674.001]
  • [Cites] Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52 [19794270.001]
  • [Cites] Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 [19838011.001]
  • [Cites] Indian J Pathol Microbiol. 1990 Apr;33(2):118-23 [2391141.001]
  • (PMID = 20565773.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2927996
  •  go-up   go-down


14. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM: Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest; 2005 Feb;115(2):339-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.
  • We used a spheroid model of colon carcinoma to analyze integrin dynamics as a function of the epithelial-mesenchymal transition (EMT), a process that provides a paradigm for understanding how carcinoma cells acquire a more aggressive phenotype.
  • This integrin enhances the tumorigenic properties of colon carcinoma, including activation of autocrine TGF-beta and migration on interstitial fibronectin.
  • Elevated receptor expression did not simply reflect increasing tumor stage, since log-rank analysis showed a more significant impact on the survival of patients with early-stage, as opposed to late-stage, disease.
  • These findings define the alphavbeta6 integrin as an important risk factor for early-stage disease and a novel therapeutic candidate for colorectal cancer.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1991 Jan;87(1):1-5 [1985087.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] J Cell Biol. 1995 May;129(3):853-65 [7537276.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51 [7673344.001]
  • [Cites] Cancer Surv. 1995;24:67-79 [7553663.001]
  • [Cites] Acta Anat (Basel). 1995;154(1):8-20 [8714286.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):5091-106 [8756667.001]
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2462-77 [8843198.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 1):L256-63 [9252563.001]
  • [Cites] Curr Biol. 1998 Nov 19;8(23):1243-52 [9822576.001]
  • [Cites] Cell. 1999 Feb 5;96(3):319-28 [10025398.001]
  • [Cites] Circ Res. 1999 May 28;84(10):1177-85 [10347092.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17875-87 [14960589.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1433-40 [10780523.001]
  • [Cites] Genes Dev. 2000 Oct 15;14(20):2610-22 [11040215.001]
  • [Cites] Mol Biol Cell. 2001 Jan;12(1):27-36 [11160820.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1537-44 [11413161.001]
  • [Cites] Exp Mol Pathol. 2001 Jun;70(3):255-64 [11418004.001]
  • [Cites] Bioessays. 2001 Oct;23(10):912-23 [11598958.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):169-73 [12634787.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):1790-800 [12802055.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] Cancer Res. 1987 May 15;47(10):2683-9 [3567898.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] J Biol Chem. 1992 Mar 25;267(9):5790-6 [1532572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1521-7 [8245410.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):403-15 [8163556.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):920 [1311835.001]
  • (PMID = 15668738.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK034854; United States / NIDDK NIH HHS / DK / DK34854; United States / NCI NIH HHS / CA / CA107548; United States / NCI NIH HHS / CA / R01 CA107548; United States / NCI NIH HHS / CA / CA 80789; United States / NCI NIH HHS / CA / R01 CA080789
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alpha5; 0 / Integrin beta Chains; 0 / Transforming Growth Factor beta; 0 / integrin beta6
  • [Other-IDs] NLM/ PMC544606
  •  go-up   go-down


16. Zuo ZG, Song HY, Li J, Xu C, Zhou ZH, Ni SC, Chen SQ: [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Dec;31(12):941-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma].
  • OBJECTIVE: To investigate the clinical application of intersphincter resection (ISR) combined with total mesorectal excision (TME) and colon-anal anastomosis in the treatment for ultra-low rectal carcinoma.
  • METHODS: To review and analyze retrospectively the data of 34 patients with ultra-low rectal carcinoma (without external anal sphincter involvement) who received treatment of ISR, TME and colon-anal anastomosis.
  • Reconstruction of digestive tract was done by manual colon-anal anastomosis.
  • The pathological types were as follows: 28 cases of adenocarcinoma (11 were well differentiated, 17 moderately differentiated), 1 case of papillary carcinoma and 5 cases of villous adenoma with malignant change.
  • The postoperative pathological stages were: Dukes stage A in 28 cases, stage B in 1 and stage C in 5 cases.
  • CONCLUSION: With strictly grasping indications, radical resection can be attained and anal sphincter preserved by ISR combined with TME and colon-anal anastomosis.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Surgical Wound Dehiscence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193339.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Chiappa A, Biffi R, Zbar AP, Luca F, Crotti C, Bertani E, Biella F, Zampino G, Orecchia R, Fazio N, Venturino M, Crosta C, Pruneri GC, Grassi C, Andreoni B: Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. Int J Colorectal Dis; 2005 May;20(3):221-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003.
  • BACKGROUND AND AIMS: This study reviewed the results of surgery for distal rectal cancer (where the tumour was within 6 cm of the anal verge) following the introduction of total mesorectal excision for rectal cancer in one institution.
  • PATIENTS AND METHODS: One hundred and fifty-three patients who had undergone elective curative surgical resection of rectal cancer within 6 cm of the anal verge were included.
  • On multivariate analysis type of surgery (P=0.025) and tumour stage (P=0.043), were associated with local recurrence, but only stage was a significant prognosticator of overall survival (P=0.0006).
  • CONCLUSION: With the practice of total mesorectal excision, APR was still necessary in 40% of patients with rectal cancer within 6 cm of the anal verge.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Postoperative Care / methods. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Oct;26(10):1272-6 [12205546.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Tech Coloproctol. 2001 Aug;5(2):97-102 [11862566.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):117-21 [2298097.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):375-9 [8665198.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Br J Surg. 1985 Jan;72(1):34-7 [3967128.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1142-9 [12190680.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):947-54 [11496074.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):117 [9102254.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):799-802 [7543403.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10 ):704-9 [11021483.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1164-70 [10504371.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):751-7 [11087640.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):643-8 [8891623.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1408-16 [3345493.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):239-43 [12657233.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):72-9 [12513964.001]
  • [Cites] Dis Colon Rectum. 1996 Mar;39(3):323-8 [8603556.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):11-5 [7851543.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):640-3 [8631412.001]
  • [Cites] Colorectal Dis. 2001 May;3(3):179-84 [12790986.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Ann Surg. 1990 Jun;211(6):745-51; discussion 751-2 [2357137.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):979-83 [9715152.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] Chir Ital. 2003 May-Jun;55(3):333-44 [12872567.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):379-84 [10201783.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):48-58 [14719151.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • (PMID = 15602647.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG: [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma].
  • OBJECTIVE: To analyze the impact of meticulousness of pathologists on the lymph node harvest after radical resection of invasive rectal carcinoma.
  • METHODS: From January 2008 to May 2009, the clinical data of rectal cancer patients undergone operation were reviewed retrospectively.
  • After multidisciplinary cooperation on rectal cancer, a new rule was applied to request the pathologists to find no less than 15 nodes in single colorectal specimen from January 2009.
  • Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal cancer (familial adenomatous polyposis, synchronous colorectal carcinoma) and rectal cancer receiving neoadjuvant chemoradiation.
  • There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to anal verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM stage (P=0.167) between the two groups.
  • The good performance of pathologists could produce adequate number of lymph nodes for rectal cancer without neoadjuvant chemoradiation.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921565.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


20. Matsopoulos GK, Mouravliansky NA, Asvestas PA, Delibasis KK, Kouloulias V: Thoracic non-rigid registration combining self-organizing maps and radial basis functions. Med Image Anal; 2005 Jun;9(3):237-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An automatic three-dimensional non-rigid registration scheme is proposed in this paper and applied to thoracic computed tomography (CT) data of patients with stage III non-small cell lung cancer (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Imaging, Three-Dimensional / methods. Lung Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Radiography, Thoracic / methods. Subtraction Technique

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854844.001).
  • [ISSN] 1361-8415
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • All were considered to have Stage N0 disease radiologically.
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Courter LA, Luch A, Musafia-Jeknic T, Arlt VM, Fischer K, Bildfell R, Pereira C, Phillips DH, Poirier MC, Baird WM: The influence of diesel exhaust on polycyclic aromatic hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo. Cancer Lett; 2008 Jun 28;265(1):135-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the influence of diesel exhaust particulate matter on PAH-induced cytochrome P450 (CYP) activity, PAH-DNA adduct formation, expression of certain candidate genes and the frequency of tumor initiation in the two-stage Sencar mouse model.
  • The applied diesel particulate matter (SRM(1975)) altered the tumor initiating potency of DBP: a statistically significant decrease in overall tumor and carcinoma burden was observed following 25 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), compared with DBP exposure alone.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DIBENZO(A,L)PYRENE .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2083-9 [7554058.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2979-84 [8674051.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):442-8 [17490615.001]
  • [Cites] Mutat Res. 2007 Dec 1;625(1-2):72-82 [17612574.001]
  • [Cites] Nat Protoc. 2007;2(11):2772-81 [18007613.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1797-810 [17944540.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):653-61 [10753200.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1742-9 [11114312.001]
  • [Cites] Hum Exp Toxicol. 2000 Oct;19(10):573-95 [11211997.001]
  • [Cites] Environ Health Perspect. 2001 Jan;109(1):71-4 [11171528.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2727-31 [11289154.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):1077-86 [11408352.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):861-8 [11510978.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):121-7 [11668486.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] JAMA. 2002 Mar 6;287(9):1132-41 [11879110.001]
  • [Cites] Mutat Res. 2002 Mar 25;515(1-2):85-98 [11909757.001]
  • [Cites] Chemosphere. 2002 Apr;47(1):57-64 [11996136.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):241-6 [12011483.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93 [12223276.001]
  • [Cites] Chem Res Toxicol. 2002 Sep;15(9):1127-35 [12230405.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1937-45 [12419844.001]
  • [Cites] Environ Res. 2003 Jul;92(3):191-6 [12804515.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):1-6 [14720319.001]
  • [Cites] Glycoconj J. 2004;19(7-9):557-63 [14758080.001]
  • [Cites] Toxicol In Vitro. 2004 Jun;18(3):377-91 [15046786.001]
  • [Cites] Environ Mol Mutagen. 2004;44(2):99-107 [15278913.001]
  • [Cites] J Invest Dermatol. 1974 Oct;63(4):343-9 [4424714.001]
  • [Cites] Int J Environ Anal Chem. 1981;9(2):93-144 [7012053.001]
  • [Cites] Carcinogenesis. 1982;3(4):371-5 [6284398.001]
  • [Cites] Cancer Lett. 1984 Oct;24(3):327-33 [6437667.001]
  • [Cites] Mol Pharmacol. 1997 Dec;52(6):974-82 [9415707.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2070-5 [9605744.001]
  • [Cites] Chem Res Toxicol. 1998 Jun;11(6):686-95 [9625737.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):151-6 [9627710.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):155-66 [10064858.001]
  • [Cites] Mutagenesis. 1999 May;14(3):301-15 [10374998.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Dec 1;201(2):178-85 [15541757.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17(12):1667-74 [15606143.001]
  • [Cites] Chem Res Toxicol. 2005 Feb;18(2):224-31 [15720126.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1251-8 [15735009.001]
  • [Cites] Crit Rev Toxicol. 2005 Jun;35(5):379-411 [16097136.001]
  • [Cites] Curr Dir Autoimmun. 2006;9:1-17 [16394652.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):845-53 [16467098.001]
  • [Cites] Chem Res Toxicol. 2006 Feb;19(2):288-94 [16485905.001]
  • [Cites] Toxicol Lett. 2006 Aug 20;165(2):182-94 [16713138.001]
  • [Cites] BMC Genomics. 2006;7:260 [17042939.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:253-65 [17119207.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):63-73 [17060372.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:263-92 [16970545.001]
  • [Cites] Mutat Res. 2007 Feb 3;615(1-2):87-97 [17141280.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1161-8 [17187366.001]
  • [Cites] Toxicology. 2007 Mar 7;231(2-3):159-74 [17240030.001]
  • [Cites] Chem Res Toxicol. 2007 Mar;20(3):489-96 [17291012.001]
  • [Cites] Cancer Res. 1987 Jul 15;47(14):3701-6 [3109730.001]
  • [Cites] Sci Total Environ. 1987 Oct;66:95-114 [3317821.001]
  • [Cites] Chem Biol Interact. 1988;68(1-2):127-36 [3203403.001]
  • [Cites] Toxicology. 1990 Jan-Feb;60(1-2):127-35 [1690463.001]
  • [Cites] Carcinogenesis. 1990 Sep;11(9):1611-9 [2401051.001]
  • [Cites] Endocrinology. 1991 Aug;129(2):970-82 [1649753.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1939-44 [1934274.001]
  • [Cites] Carcinogenesis. 1992 Jul;13(7):1053-74 [1638670.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):875-8 [8504480.001]
  • [Cites] N Engl J Med. 1993 Dec 9;329(24):1753-9 [8179653.001]
  • [Cites] Environ Health Perspect. 1993 Dec;101 Suppl 4:155-65 [7515806.001]
  • [Cites] Mol Carcinog. 1994 Jul;10(3):159-68 [8043197.001]
  • (PMID = 18353537.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / R01 CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825-19; United States / NCI NIH HHS / CA / CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825; United States / NCI NIH HHS / CA / CA028825-19; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / R01 CA028825-23; United States / NCI NIH HHS / CA / CA028825-22; United States / NCI NIH HHS / CA / CA28825; United States / NCI NIH HHS / CA / CA028825-20; United States / NCI NIH HHS / CA / R01 CA028825-20; United States / NCI NIH HHS / CA / CA028825-24; United States / NCI NIH HHS / CA / R01 CA028825-22; United States / NIEHS NIH HHS / ES / T32 ES007060; United States / NCI NIH HHS / CA / R01 CA028825-24; United States / NIEHS NIH HHS / ES / P30 ES000210; United States / NCI NIH HHS / CA / CA028825-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzopyrenes; 0 / Carcinogens; 0 / DNA Adducts; 0 / Particulate Matter; 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Vehicle Emissions; 0 / polycyclic aromatic hydrocarbons-DNA adduct; 191-30-0 / dibenzo(a,l)pyrene; 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS53855; NLM/ PMC2519885
  •  go-up   go-down


23. Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H: [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr; 2006 Aug 25;131(34-35):1849-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data were collected on all AIDS- and not-AIDS-defined haematological malignancies and all AIDS- and not-AIDS-defined solid malignant tumors in HIV-positive patients, as well as on time of diagnosis of the malignancy, tumor stage, tumor treatment and response to treatment.
  • Of the 200 (52.6%) not-AIDS-defined malignant tumors 133 were 133 solid tumors, 40 of them anal carcinoma (20% of all not-AIDS-defined malignancies) and 67 haematological malignancies, 22 of these Hodgkin's lymphoma (11.0% of all not-AIDS-defined malignancies).
  • The incidence of anal carcinoma is estimated to be 34 (95% CI 24-470) per 100 000 patient-years, that of Hodgkin's lymphoma 19 (95% CI 12-28) per 100 000 patient-years.
  • Of special note is the high incidence of anal carcinoma and Hodgkin's lymphoma, compared with their incidence among the entire German population.
  • [MeSH-major] Anus Neoplasms / epidemiology. HIV Infections / complications. Hodgkin Disease / epidemiology. Neoplasms / epidemiology. Neoplasms / virology
  • [MeSH-minor] Carcinoma / epidemiology. Female. Germany / epidemiology. Humans. Incidence. Male. Retrospective Studies. Sex Factors. Surveys and Questionnaires


24. Helpap B, Egevad L: Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. Anal Quant Cytol Histol; 2008 Jun;30(3):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
  • STUDY DESIGN: A total of 828 consecutive needle biopsy specimens of prostate carcinoma were collected from the years 1995 and 2000 (graded with conventional Gleason grading) and 2006 and 2007 (graded with modified Gleason grading).
  • RESULTS: Both conventional and modified Gleason grading correlated with age, serum PSA, percent positive biopsies and percent cancer length.
  • Serum PSA and percent positive cores were lower than in the 1995 and 2000 group, indicating a stage shift downward, but the Gleason scores were nevertheless higher.
  • CONCLUSION: Conventional and modified Gleason grading both correlated with age, serum PSA and cancer involvement in needle biopsies.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630837.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


25. Nair KS, Naidoo R, Chetty R: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol; 2005 Apr;58(4):343-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.
  • Oesophageal carcinoma remains a disease of poor prognosis.
  • Surgical cure rates are compromised by the fact that most patients are diagnosed at a late stage of disease because of the delayed onset of symptoms, by which time metastases and organ infiltration may have already occurred.
  • This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in squamous cell carcinoma and adenocarcinoma of the oesophagus.
  • [MeSH-minor] Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis. Carcinoma, Squamous Cell / chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 Jan;32(1):7-14 [9522210.001]
  • [Cites] J Cell Physiol. 1998 Sep;176(3):482-94 [9699501.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):858-66 [9731887.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):463S-465S [10619509.001]
  • [Cites] Mol Pathol. 1999 Aug;52(4):189-96 [10694938.001]
  • [Cites] Mol Pathol. 1999 Aug;52(4):208-13 [10694941.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):677-82 [10717234.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):725-9 [10717240.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] J Cell Biol. 2000 Aug 7;150(3):567-80 [10931868.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):701-5 [10995880.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):19-26 [11029766.001]
  • [Cites] Cell Biol Int. 2001;25(1):61-9 [11237409.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):624-30 [11274010.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):981-5 [11496302.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3519-25 [11705871.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):999-1006 [11956235.001]
  • [Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]
  • [Cites] Annu Rev Biochem. 1991;60:155-90 [1883195.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] J Cell Biol. 1991 Dec;115(6):1751-61 [1757472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292-6 [1372439.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Cell. 1992 Apr 17;69(2):225-36 [1568244.001]
  • [Cites] J Pathol. 1992 May;167(1):77-82 [1625062.001]
  • [Cites] J Pathol. 1992 Jun;167(2):187-91 [1378891.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Lancet. 1992 Oct 31;340(8827):1053-8 [1357452.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):629-34 [1384639.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):577-85 [8381117.001]
  • [Cites] Lancet. 1993 Mar 20;341(8847):725-6 [8095628.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):981-6 [7682766.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] J Surg Oncol. 1993 Jun;53(2):78-83 [8501910.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):431-42 [8320265.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):428-32 [8347502.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4197-203 [7689929.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22883-94 [8226797.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):630-1 [7505052.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):695-8 [7505053.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):291-6 [8261454.001]
  • [Cites] Cell. 1994 Jan 28;76(2):301-14 [7507411.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):589-600 [8106556.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1324-31 [7906606.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3007-10 [8187090.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1327-40 [8207061.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):425-30 [8042040.001]
  • [Cites] J Cell Biol. 1994 Aug;126(4):1099-109 [7519619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8263-7 [8058792.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26602-5 [7929388.001]
  • [Cites] J Cell Physiol. 1997 Oct;173(1):54-63 [9326449.001]
  • [Cites] J Pathol. 1997 Jul;182(3):331-8 [9349237.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4039-45 [9354673.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):582-7 [9421352.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1421-31 [9182672.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1074-80 [9740070.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1097-102 [9816273.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):402-12 [8954713.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1608-14 [9014688.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):407-10 [9516929.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):1-5 [9202049.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] J Pathol. 1998 Sep;186(1):1-2 [9875132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44 [9874785.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1311-22 [10087272.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] Am J Med. 1999 Apr;106(4):467-76 [10225251.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):938-43 [10370643.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):369-76 [10392898.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21409-15 [10409703.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):591-6 [10508646.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1849-57 [12168881.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):953-65 [12213839.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):225-32 [12532436.001]
  • [Cites] Surgery. 2003 Feb;133(2):162-9 [12605177.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):161-5 [12680208.001]
  • [Cites] J Neurosurg. 2003 May;98(5):1084-93 [12744370.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6a):4435-42 [14666731.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):1-7 [2998604.001]
  • [Cites] J Cell Biol. 1987 May;104(5):1361-74 [3553211.001]
  • [Cites] J Exp Med. 1987 Oct 1;166(4):1125-31 [3655655.001]
  • [Cites] J Pathol. 1988 Jul;155(3):207-12 [3411381.001]
  • [Cites] Development. 1988 Apr;102(4):639-55 [3048970.001]
  • [Cites] Biochim Biophys Acta. 1988 Nov 15;948(2):175-224 [3052592.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1303-6 [2588007.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1990 Feb 15;50(4):1271-8 [1967552.001]
  • [Cites] J Cell Biol. 1990 Feb;110(2):349-57 [2153683.001]
  • [Cites] Cell. 1990 Feb 23;60(4):577-84 [1689216.001]
  • [Cites] Cancer Metastasis Rev. 1989 Dec;8(3):263-80 [2697474.001]
  • [Cites] Science. 1990 Mar 9;247(4947):1219-22 [1690453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4246-50 [2349235.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1303-13 [1694723.001]
  • [Cites] Nature. 1990 Aug 2;346(6283):425-34 [1974032.001]
  • [Cites] FASEB J. 1990 Aug;4(11):2868-80 [2199285.001]
  • [Cites] Lab Invest. 1990 Dec;63(6):780-91 [1979361.001]
  • [Cites] Cell. 1991 May 31;65(5):849-57 [1904011.001]
  • [Cites] Cell. 1991 Jul 12;66(1):107-19 [2070412.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6282-7 [7954478.001]
  • [Cites] Gut. 1994 Oct;35(10):1343-7 [7959182.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9 [7806582.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):663-73 [7530461.001]
  • [Cites] Cell. 1995 Feb 10;80(3):413-22 [7532110.001]
  • [Cites] Nature. 1995 Mar 23;374(6520):327-37 [7885471.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5549-55 [7890674.001]
  • [Cites] J Cell Biol. 1995 Jul;130(1):67-77 [7790378.001]
  • [Cites] FASEB J. 1995 Jul;9(10):866-73 [7542213.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):451-60 [7542249.001]
  • [Cites] Mol Biol Cell. 1995 Apr;6(4):419-31 [7542940.001]
  • [Cites] J Clin Pathol. 1995 Jun;48(6):539-44 [7665697.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8813-7 [7568023.001]
  • [Cites] J Pathol. 1995 Sep;177(1):11-20 [7472774.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1823-39 [7495306.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):634-40 [8573337.001]
  • [Cites] Science. 1996 Apr 5;272(5258):60-6 [8600538.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):183-91 [8603368.001]
  • [Cites] Br J Surg. 1996 May;83(5):588-601 [8689199.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):158-65 [9075789.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):124-38 [10564536.001]
  • [Cites] Gut. 2000 Jan;46(1):14-9 [10601048.001]
  • (PMID = 15790695.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Integrins; 0 / Selectins
  • [Number-of-references] 132
  • [Other-IDs] NLM/ PMC1770622
  •  go-up   go-down


26. Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, Glynne-Jones R: Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?
  • PURPOSE: To describe the MRI appearances of squamous cell carcinoma of the anal canal before and after chemoradiation and to assess whether MRI features predict for clinical outcome.
  • METHODS AND MATERIALS: Thirty-five patients (15 male, 20 female; mean age 60.8 years) with histologically proven squamous cell cancer of the anal canal underwent MRI before and 6-8 weeks after definitive chemoradiation.
  • Images were reviewed retrospectively by two radiologists in consensus blinded to clinical outcome: tumor size, signal intensity, extent, and TNM stage were recorded.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Anal Canal / pathology. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171812.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H: Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg; 2010 Nov;395(8):1031-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal cancer patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
  • It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal cancer patients using a representative data set from the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal Cancer Surgery prospective multicenter observational trial.
  • Data of all patients undergoing curatively intended sphincter-preserving resection for UICC stage I through III rectal carcinoma between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
  • Significant differences were present between groups regarding age, sex, distance of the tumor from the anal verge, pT-stage, UICC stage, hepatic risk factors, and use of protective enterostomy by univariate analysis.
  • CONCLUSION: Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.
  • [MeSH-major] Anal Canal / surgery. Anastomotic Leak / etiology. Neoadjuvant Therapy. Postoperative Complications / etiology. Quality Assurance, Health Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectum / surgery. Urinary Bladder Diseases / etiology


28. Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ: Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol; 2008 Apr 28;14(16):2474-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, nonalcoholic fatty liver disease (NAFLD) has been used as a general name for conditions ranging from simple steatosis through steatohepatitis to end-stage liver disease (cirrhosis).
  • Longitudinal cohort studies have demonstrated that those patients with cirrhosis have a similar risk to develop hepatocellular carcinoma as those with other causes of cirrhosis.

  • Genetic Alliance. consumer health - Liver Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):639-44 [16630771.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Diabetes. 2006 Jun;55(6):1537-45 [16731815.001]
  • [Cites] Dig Liver Dis. 2006 Jul;38(7):485-9 [16716779.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2552-63 [16775236.001]
  • [Cites] Minerva Cardioangiol. 2006 Apr;54(2):229-39 [16778754.001]
  • [Cites] Radiology. 2006 Jul;240(1):116-29 [16684918.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):462-9 [16799888.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1767-75 [16823474.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):934-45 [16952562.001]
  • [Cites] Eur Radiol. 2006 Oct;16(10):2292-308 [16477402.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54 [16608888.001]
  • [Cites] Hepatology. 2006 Oct;44(4):802-5 [17006914.001]
  • [Cites] Hepatology. 2006 Oct;44(4):865-73 [17006923.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):379; author reply 380 [16520485.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):346-51 [16534679.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Apr;18(4):411-2 [16538113.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S11-6 [16540761.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1702-4 [12404244.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1705-25 [12404245.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi [17544979.001]
  • [Cites] N Engl J Med. 2007 Jun 14;356(24):2457-71 [17517853.001]
  • [Cites] Med Mol Morphol. 2007 Jun;40(2):55-67 [17572841.001]
  • [Cites] Hepatology. 2007 Jul;46(1):122-9 [17526015.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):28-38 [17551159.001]
  • [Cites] Horm Res. 2007;68(2):72-82 [17344645.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34182-90 [12097330.001]
  • [Cites] Dig Dis Sci. 2007 Oct;52(10):2512-9 [17404856.001]
  • [Cites] Annu Rev Nutr. 2007;27:179-92 [17428181.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):656-60 [10604470.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):272-6 [10638596.001]
  • [Cites] Cleve Clin J Med. 2000 Feb;67(2):96-7, 101-4 [10680276.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):734-8 [10839868.001]
  • [Cites] Br J Nutr. 2000 Mar;83 Suppl 1:S5-8 [10889785.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):77-86 [10949029.001]
  • [Cites] Nat Med. 2000 Sep;6(9):998-1003 [10973319.001]
  • [Cites] Eur J Pharmacol. 2000 Oct 6;406(1):R5-7 [11011050.001]
  • [Cites] Genes Dev. 2000 Nov 15;14(22):2831-8 [11090131.001]
  • [Cites] Trends Endocrinol Metab. 2003 Nov;14(9):398-403 [14580758.001]
  • [Cites] Am J Med. 2003 Nov;115(7):554-9 [14599635.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2485-90 [14638353.001]
  • [Cites] Endocr Pract. 2003 Sep-Oct;9 Suppl 2:93-6 [14698985.001]
  • [Cites] Hepatology. 2004 Jan;39(1):188-96 [14752837.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Mar 1;19(5):537-44 [14987322.001]
  • [Cites] Hepatology. 2004 Mar;39(3):754-63 [14999694.001]
  • [Cites] Hepatology. 2004 Mar;39(3):770-8 [14999696.001]
  • [Cites] Hepatology. 2004 Apr;39(4):1172; author reply 1173 [15057921.001]
  • [Cites] Curr Opin Pediatr. 2005 Oct;17(5):636-41 [16160540.001]
  • [Cites] Liver Int. 2005 Oct;25(5):921-6 [16162147.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:3-10 [16225463.001]
  • [Cites] Turk J Gastroenterol. 2005 Sep;16(3):124-8 [16245220.001]
  • [Cites] Hepatology. 2005 Nov;42(5):987-1000 [16250043.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1805 [16285987.001]
  • [Cites] Ann Intern Med. 2005 Nov 15;143(10):722-8 [16287793.001]
  • [Cites] Radiology. 2005 Dec;237(3):1048-55 [16237138.001]
  • [Cites] Am J Med Sci. 2005 Dec;330(6):280-9 [16355012.001]
  • [Cites] Hepatology. 2006 Jan;43(1):64-71 [16374856.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):207-10 [16401483.001]
  • [Cites] Nihon Koshu Eisei Zasshi. 2005 Nov;52(11):934-42 [16408478.001]
  • [Cites] Mitochondrion. 2006 Feb;6(1):1-28 [16406828.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96 [16493415.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):379-80; author reply 380 [16520484.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Mar;23(2):193-8 [17268250.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):532-41 [17118991.001]
  • [Cites] Am J Med. 2007 Feb;120(2 Suppl 1):S9-17; discussion S29-32 [17296344.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2007 Feb;17(2):125-39 [17270403.001]
  • [Cites] Transl Res. 2007 Mar;149(3):114-25 [17320797.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):686-92 [17272484.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10 [17264176.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1232-4 [17409342.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 May;27(5):1108-14 [17303778.001]
  • [Cites] Diab Vasc Dis Res. 2007 Mar;4(1):32-8 [17469041.001]
  • [Cites] Hepatology. 2007 May;45(5):1108-17 [17464987.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2087-102 [17498505.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2169-80 [17498510.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):307-12 [11201732.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):729-33 [11217863.001]
  • [Cites] Endocr Pract. 2001 Jan-Feb;7(1):44-51 [11250769.001]
  • [Cites] Liver Transpl. 2001 May;7(5):409-14 [11349260.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1631-4 [11374713.001]
  • [Cites] Anal Biochem. 2001 Jul 1;294(1):73-82 [11412008.001]
  • [Cites] Nat Med. 2001 Jul;7(7):827-32 [11433348.001]
  • [Cites] Eur J Ultrasound. 2001 Dec;14(2-3):121-8 [11704429.001]
  • [Cites] Obes Res. 2001 Nov;9 Suppl 4:228S-233S [11707546.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1158-63 [11732005.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):570-8 [11856796.001]
  • [Cites] Gut. 2001 Feb;48(2):206-11 [11156641.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20314-26 [14985368.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Apr;5(4):389-94 [15134279.001]
  • [Cites] J Gastroenterol. 2004;39(4):391-6 [15168253.001]
  • [Cites] Eur J Heart Fail. 2004 Jun;6(4):501-8 [15182777.001]
  • [Cites] Clin Liver Dis. 2004 Aug;8(3):575-94, ix [15331065.001]
  • [Cites] J Clin Gastroenterol. 2005 Aug;39(7):619-25 [16000931.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):113-21 [16012941.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):375-8 [16012969.001]
  • [Cites] Nature. 2005 Jul 21;436(7049):356-62 [16034410.001]
  • [Cites] Diabetes. 2005 Sep;54(9):2668-73 [16123356.001]
  • [Cites] Hepatology. 2005 Sep;42(3):650-6 [16037946.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S34-8 [16540765.001]
  • [Cites] Magn Reson Med. 2006 Apr;55(4):913-7 [16506186.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Apr;64(4):355-65 [16584505.001]
  • [Cites] Obesity (Silver Spring). 2006 Feb;14 Suppl 1:16S-19S [16642958.001]
  • [Cites] Mayo Clin Proc. 2006 Dec;81(12):1615-20 [17165640.001]
  • [Cites] Nature. 2006 Dec 14;444(7121):840-6 [17167471.001]
  • [Cites] Nature. 2006 Dec 14;444(7121):847-53 [17167472.001]
  • [Cites] Eur J Radiol. 2007 Jan;61(1):33-43 [17118603.001]
  • [Cites] Diabet Med. 2007 Jan;24(1):1-6 [17227317.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005160 [17253541.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005165 [17253543.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005166 [17253544.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1125-31 [11994399.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;967:379-88 [12079865.001]
  • [Cites] Pharmacol Ther. 2002 Aug;95(2):103-17 [12182958.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2117-9 [12190187.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):745-50 [12198701.001]
  • [Cites] J R Soc Med. 2002;95 Suppl 42:39-45 [12216326.001]
  • [Cites] Clin Liver Dis. 2004 Aug;8(3):619-38, x [15331067.001]
  • [Cites] Indian J Gastroenterol. 2004 Jul-Aug;23(4):131-4 [15333967.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):623-8 [15352910.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1946-52 [15447754.001]
  • [Cites] Science. 2004 Oct 15;306(5695):457-61 [15486293.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1095-105 [15489566.001]
  • [Cites] Ann Hepatol. 2004 Jul-Sep;3(3):108-12 [15505596.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Mol Pharmacol. 1988 Nov;34(5):605-13 [2848184.001]
  • [Cites] Nature. 1990 Aug 9;346(6284):561-4 [2165569.001]
  • [Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2409-15 [7738205.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):54-61 [7556170.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Apr 16;221(2):286-9 [8619847.001]
  • [Cites] Hepatology. 1998 Jan;27(1):128-33 [9425928.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):842-5 [9547102.001]
  • [Cites] FASEB J. 1998 Aug;12(11):1035-44 [9707176.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 1):E977-89 [10329993.001]
  • [Cites] J Hepatol. 1999 Aug;31(2):384 [10453959.001]
  • [Cites] Dtsch Med Wochenschr. 1962 May 18;87:1049-55 [13920482.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:180-210 [13920484.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2365-8 [15571584.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):101-10 [15603755.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15 [15625656.001]
  • [Cites] Biochimie. 2005 Jan;87(1):57-64 [15733738.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1578-82 [15598693.001]
  • [Cites] Front Biosci. 2005;10:1520-33 [15769642.001]
  • [Cites] Lancet. 2005 Apr 16-22;365(9468):1389-97 [15836887.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1072-81 [15842581.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1082-90 [15842582.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1298-305 [15864349.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1343-51 [15864352.001]
  • [Cites] Int J Clin Pract. 2006 Dec;60(12):1697-706 [17109677.001]
  • [Cites] BMC Gastroenterol. 2006;6:34 [17096854.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2297-307 [17135584.001]
  • [Cites] Metabolism. 2006 Dec;55(12):1604-9 [17142131.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4753-61 [16968800.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2006 Dec;20(4):665-79 [17161338.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45904-10 [12270935.001]
  • [Cites] Nature. 2002 Nov 21;420(6913):333-6 [12447443.001]
  • [Cites] Hepatology. 2003 Mar;37(3):544-50 [12601351.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 May;15(5):539-43 [12702913.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):926-30 [12738478.001]
  • [Cites] Braz J Med Biol Res. 2003 Jun;36(6):723-9 [12792701.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):91-100 [12840063.001]
  • [Cites] Rom J Gastroenterol. 2003 Sep;12(3):189-92 [14502318.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1008-17 [14512888.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1167-77 [14578855.001]
  • (PMID = 18442193.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fatty Acids, Nonesterified; 0 / Leptin; 0 / Lipids
  • [Number-of-references] 152
  • [Other-IDs] NLM/ PMC2708357
  •  go-up   go-down


29. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


30. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • The T-stage according to the 2001 UICC classification were: 2 T1, 26 T2, 25 T3, and 7 T4.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Bretagnol F, Merrie A, George B, Warren BF, Mortensen NJ: Local excision of rectal tumours by transanal endoscopic microsurgery. Br J Surg; 2007 May;94(5):627-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, its role in the curative treatment of invasive carcinoma is controversial.
  • The median tumour distance from the anal verge was 8 (range 1-16) cm.
  • Histological examination of carcinomas revealed pathological tumour (pT) stage 1 in 31 patients, pT2 in 17 and pT3 in four.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2007 Sep;94(9):1179; author reply 1179 [17701963.001]
  • (PMID = 17335125.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Kato T, Takagi H, Mori Y, Sakamoto K, Yamada T, Umeda Y, Fukumoto Y, Hirose H: Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer. Heart Vessels; 2005 Jul;20(4):167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer.
  • A 68-year-old man with ischemic heart disease, abdominal aortic aneurysm, and rectal cancer was referred.
  • Barium enema revealed stenosis 4 cm in length 5 cm inward from the anal verge, and an endoscopic finding was ulcerated type tumor with a clear margin and circumferential stenosis.
  • Histological examination of a biopsy specimen revealed adenocarcinoma, and the clinical stage in the Japanese classification of colorectal carcinoma was II according to other examinations.
  • Simultaneous operations were scheduled because of the jeopardized collaterals of the coronary arteries, rapid expansion of the aneurysm, and subileus due to the cancer.
  • The patient is doing well 12 months after the operation, without myocardial ischemic symptoms or recurrence of the cancer.


33. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park); 2010 Apr 30;24(5):417-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
  • The treatment of anal squamous cell cancer with definitive chemoradiation is the gold-standard therapy for localized anal cancer, primarily because of its sphincter-saving and colostomy-sparing potential.
  • In the concluding part of this review, we consider the data on chemoradiation with 5-FU/mitomycin vs radiation alone, chemoradiation with 5-FU/mitomycin vs chemoradiation with 5-FU alone, neoadjuvant chemotherapy with cisplatin/5-FU followed by cisplatin/5-FU plus radiation vs mitomycin/5-FU plus radiation, the addition of induction or maintenance chemotherapy to chemoradiation, the effect of overall treatment time on tumor control, whether chemotherapy can be eliminated for early-stage anal cancer, and the impact of human immunodeficiency virus infection on treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Apr 30;24(5):427-30 [20480742.001]
  • [CommentIn] Oncology (Williston Park). 2010 Apr 30;24(5):424-7 [20480741.001]
  • (PMID = 20480740.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


34. Dwyer MK, Gebski VJ, Jayamohan J: The bottom line: outcomes after conservation treatment in anal cancer. Australas Radiol; 2006 Feb;50(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bottom line: outcomes after conservation treatment in anal cancer.
  • At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell carcinoma of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil).
  • Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499727.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, Aust G: Expression of ADAM15 in lung carcinomas. Virchows Arch; 2005 Apr;446(4):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung carcinoma cell lines and tissues.
  • Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell cancer (SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex.
  • Overall analysis of all tumor specimens and each tumor type revealed no significant correlation between tumor stage or degree of differentiation and ADAM15 ectosolic or cytosolic domain expression in tumor cells.
  • In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Integrin alphaVbeta3 / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Metalloendopeptidases / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):260-7 [8751559.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):437-42 [9199213.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):579-87 [9914169.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33683-9 [12091380.001]
  • [Cites] Differentiation. 1988;37(2):158-71 [2840315.001]
  • [Cites] Haematologica. 2002 Aug;87(8):836-45 [12161360.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]
  • [Cites] Pathol Res Pract. 1998;194(10):701-4 [9820866.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2062-9 [15026344.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):26236-47 [9748307.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):34922-30 [10944520.001]
  • [Cites] J Biol Chem. 1996 Mar 1;271(9):4593-6 [8617717.001]
  • [Cites] Thromb Haemost. 2003 Apr;89(4):622-31 [12669115.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1323-32 [8794871.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5614-24 [12897135.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Mol Immunol. 1987 Jul;24(7):699-705 [3309626.001]
  • [Cites] Trends Cell Biol. 1994 Jul;4(7):256-61 [14731666.001]
  • [Cites] Eur Respir J. 1998 Feb;11(2):400-7 [9551745.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):717-25 [12553378.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17804-10 [11882657.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):191-4 [11988838.001]
  • [Cites] Oncol Res. 1993;5(10-11):441-51 [8054705.001]
  • [Cites] Pathobiology. 2004;71(4):185-92 [15263807.001]
  • [Cites] Biochem Soc Trans. 1999 Feb;27(2):255-9 [10093743.001]
  • [Cites] Anal Biochem. 1984 Feb;136(2):458-64 [6721145.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1129-41 [11891209.001]
  • [Cites] Pathol Int. 1995 Jul;45(7):493-500 [7551009.001]
  • [Cites] J Cell Biol. 2004 Mar 15;164(6):935-41 [15024036.001]
  • [Cites] Arthritis Rheum. 1999 Sep;42(9):1946-50 [10513811.001]
  • [Cites] Arthritis Rheum. 2001 Sep;44(9):2046-54 [11592366.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1018-25 [9308725.001]
  • [Cites] J Comp Neurol. 2003 Oct 6;465(1):1-10 [12926012.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7345-50 [9516430.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):62-70 [175022.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1209-14 [14973118.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1554-60 [9108459.001]
  • [Cites] Jpn J Cancer Res. 1996 May;87(5):451-8 [8641981.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15490-7 [10809781.001]
  • [Cites] Genes Dev. 2003 Jan 1;17(1):7-30 [12514095.001]
  • [Cites] Exp Cell Res. 2001 Nov 15;271(1):152-60 [11697891.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):275-8 [7593158.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):169-78 [9874573.001]
  • [Cites] FASEB J. 1997 Feb;11(2):173-80 [9039960.001]
  • [Cites] J Cancer Res Clin Oncol. 1980 Jan;96(1):27-33 [7358770.001]
  • (PMID = 15756594.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM15 protein, human; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


37. Dhamanaskar KP, Thurston W, Wilson SR: Transvaginal sonography as an adjunct to endorectal sonography in the staging of rectal cancer in women. AJR Am J Roentgenol; 2006 Jul;187(1):90-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transvaginal sonography as an adjunct to endorectal sonography in the staging of rectal cancer in women.
  • OBJECTIVE: The purpose of this study was to evaluate the contribution of transvaginal sonography (TVS) in the staging of rectal cancer in women.
  • Forty-nine of the women had rectal carcinoma; nine, tubulovillous adenoma; and two, gastrointestinal stromal tumor confirmed at surgical pathologic examination (n = 41) and biopsy before chemoradiation therapy (n = 19).
  • Endorectal sonography was suboptimal for tumors that were stenotic (n = 3), large (n = 2), high at the rectosigmoid junction (n = 4), or low at the anal canal (n = 3).
  • In these 12 cases, TVS successfully depicted the lesion, and the images gave enough information for prediction of stage.
  • CONCLUSION: TVS is an excellent adjunct to endorectal sonography in the staging of rectal cancer in women.
  • [MeSH-minor] Adenoma, Villous / pathology. Adenoma, Villous / ultrasonography. Aged. Carcinoma / pathology. Carcinoma / ultrasonography. Female. Humans. Middle Aged. Sensitivity and Specificity. Vagina

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794161.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y: Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol; 2006 Sep;13(9):1254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
  • Small-cell carcinoma of the prostate (SCCP) is a rare entity.
  • Case 1 involved a 53-year-old man diagnosed with SCCP after receiving hormone therapy for prostate cancer (stage D1).
  • Initially the primary site reduced according with a decline of neuro-specific enolase and with relief of the symptoms; however, bone disease occurred and he died of cancer 13 months after diagnosis of SCCP.
  • Case 2 involved a 69-year-old man complaining of severe anal pain.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984566.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


39. Uto H, Kanmura S, Takami Y, Tsubouchi H: Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci; 2010;8:70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk factor for HCC.
  • Early diagnosis of HCC and assessment of the stage of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic interventions and an improve prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2010 Apr 5;9(4):1923-30 [20121168.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Aug;136(8):1151-9 [20130913.001]
  • [Cites] Proteome Sci. 2010;8:5 [20181094.001]
  • [Cites] Biochemistry (Mosc). 2009 Dec;74(13):1575-85 [20210710.001]
  • [Cites] J Proteome Res. 2010 Jun 4;9(6):3218-24 [20441224.001]
  • [Cites] Hepatology. 1994 Jan;19(1):61-6 [7506227.001]
  • [Cites] Clin Chem. 2005 Feb;51(2):328-35 [15590748.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):377-86 [15822913.001]
  • [Cites] Anal Bioanal Chem. 2005 Jun;382(3):669-78 [15900442.001]
  • [Cites] Hepatology. 2005 Sep;42(3):665-74 [16116632.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2236-44 [16239339.001]
  • [Cites] Proteomics. 2006 Feb;6(3):1049-57 [16400691.001]
  • [Cites] Proteomics. 2006 May;6(9):2895-902 [16586431.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2189-97 [16762639.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2691-700 [17022640.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7604-12 [17171788.001]
  • [Cites] Hepatology. 2007 Apr;45(4):948-56 [17393466.001]
  • [Cites] Anal Bioanal Chem. 2007 Jun;388(3):637-43 [17447055.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):825-34 [17516088.001]
  • [Cites] Hepatology. 2007 Sep;46(3):649-57 [17654742.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Aug;4(8):432-41 [17667992.001]
  • [Cites] Clin Chem. 2007 Oct;53(10):1792-9 [17702858.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Sep 15;26(6):847-58 [17767469.001]
  • [Cites] J Proteome Res. 2008 Feb;7(2):603-10 [18189345.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):505-8 [18365545.001]
  • [Cites] Hepatology. 2008 Aug;48(2):519-30 [18571811.001]
  • [Cites] Methods Mol Biol. 2008;484:177-92 [18592180.001]
  • [Cites] J Viral Hepat. 2009 Jun;16(6):418-29 [19226329.001]
  • [Cites] J Biol Chem. 2009 Aug 7;284(32):21165-76 [19531480.001]
  • [Cites] J Viral Hepat. 2010 Nov;17(11):816-24 [20002297.001]
  • [Cites] Science. 1999 Jul 2;285(5424):110-3 [10390360.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):544-9 [10649245.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):1036-40 [10763956.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Glycobiology. 2001 Apr;11(4):275-81 [11358876.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):235-8 [11941963.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):304-13 [12096112.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Hepatology. 2003 May;37(5):1114-21 [12717392.001]
  • [Cites] Proteomics. 2003 May;3(5):666-74 [12748946.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(14):1642-50 [12845591.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):399-409 [14726492.001]
  • [Cites] Nat Med. 2004 Apr;10(4):429-34 [15152612.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]
  • [Cites] J Virol. 2005 Jun;79(12):7558-69 [15919910.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4581-8 [16240287.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):287-92 [16404431.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):111-7 [16431313.001]
  • [Cites] J Proteome Res. 2006 Feb;5(2):308-15 [16457596.001]
  • [Cites] Am J Gastroenterol. 2006 Sep;101(9):2038-43 [16848811.001]
  • [Cites] Nat Protoc. 2006;1(6):2650-60 [17406521.001]
  • [Cites] Clin Chem. 2007 Jul;53(7):1254-63 [17510303.001]
  • [Cites] J Cell Biochem. 2008 Feb 15;103(3):740-52 [17557278.001]
  • [Cites] Mol Cell Proteomics. 2007 Oct;6(10):1798-808 [17627933.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):470-7 [18223221.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3257-62 [18646007.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1998-2018 [18667411.001]
  • [Cites] Hepatology. 2008 Dec;48(6):1851-63 [18937283.001]
  • [Cites] Hepatology. 2009 Apr;49(4):1257-66 [19177598.001]
  • [Cites] Methods Mol Biol. 2009;527:173-90, ix [19241013.001]
  • [Cites] Hepatology. 2009 Apr;49(4):1375-84 [19330863.001]
  • [Cites] J Proteome Res. 2010 Jan;9(1):70-8 [19522540.001]
  • [Cites] Proteomics. 2009 Jun;9(12):3395-408 [19562805.001]
  • [Cites] Proteomics. 2009 Aug;9(15):3856-68 [19639599.001]
  • [Cites] BMC Cancer. 2009;9:271 [19656391.001]
  • [Cites] Proteomics. 2009 Aug;9(16):3989-99 [19658107.001]
  • [Cites] Hepatology. 2010 Jan;51(1):111-20 [19885878.001]
  • [Cites] J Proteome Res. 2010 Jan;9(1):308-18 [19899825.001]
  • [Cites] Int J Oncol. 2010 Jan;36(1):93-9 [19956837.001]
  • [Cites] J Gastroenterol. 2010 Apr;45(4):459-67 [20012107.001]
  • [Cites] J Proteomics. 2010 Jun 16;73(8):1421-32 [20026004.001]
  • (PMID = 21192835.001).
  • [ISSN] 1477-5956
  • [Journal-full-title] Proteome science
  • [ISO-abbreviation] Proteome Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3023778
  •  go-up   go-down


40. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer; 2007 Oct 12;7:192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.
  • BACKGROUND: It has recently been shown that NDRG2 mRNA is down-regulated or undetectable in several human cancers and cancer cell-lines.
  • The aim of this study has been to examine NDRG2 mRNA expression in colon cancer.
  • When comparing adenomas/carcinomas with adjacent normal tissue from the same individual, NDRG2 expression levels were significantly reduced in both high-risk adenoma (p < 0.001) and in colorectal carcinoma (p < 0.001).
  • There was a trend for NDRG2 levels to decrease with increasing Dukes' stage (p < 0.05).
  • CONCLUSION: Our results demonstrate that expression of NDRG2 is down-regulated at a late stage during colorectal carcinogenesis.
  • Future studies are needed to address whether NDRG2 down-regulation is a cause or consequence of the progression of colorectal adenomas to carcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] Proteins. 2002 May 1;47(2):163-8 [11933063.001]
  • [Cites] Mol Cell Biochem. 2002 Jan;229(1-2):35-44 [11936845.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):635-42 [12825872.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):342-7 [12845671.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):413-8 [14572661.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):48-58 [15207261.001]
  • [Cites] Mech Dev. 1999 May;83(1-2):39-52 [10381566.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3518-21 [15526377.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):672-5 [16042571.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):111-21 [16247483.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39159-68 [17050536.001]
  • (PMID = 17935612.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NDRG2 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2099434
  •  go-up   go-down


41. Oh JJ, Boctor BN, Jimenez CA, Lopez R, Koegel AK, Taschereau EO, Phan DT, Jacobsen SE, Slamon DJ: Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus. Hum Genet; 2008 Feb;123(1):55-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus.
  • Loss of heterozygosity (LOH) at chromosome 3p21.3 is one of the most prevalent genetic disturbances occurring at the earliest stage of tumor development for a wide variety of human cancers, culminated in lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Cell Cycle Proteins / genetics. Chromosomes, Human, Pair 3. DNA Methylation. DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Lung Neoplasms / genetics. Promoter Regions, Genetic. RNA-Binding Proteins / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33654-63 [12084718.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Apr 15;174(2):100-10 [17452250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1048-61 [11850822.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3419-27 [16585163.001]
  • [Cites] Biochim Biophys Acta. 2005 Jul 25;1730(1):66-76 [16005989.001]
  • [Cites] Future Oncol. 2005 Feb;1(1):79-92 [16555978.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):839-47 [15027117.001]
  • [Cites] Blood. 2007 Jul 1;110(1):323-33 [17360941.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7283-301 [17533367.001]
  • [Cites] Cell Biochem Funct. 2007 Nov-Dec;25(6):643-53 [16927403.001]
  • [Cites] Ai Zheng. 2007 Jan;26(1):9-14 [17222360.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6438-43 [15374952.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2715-20 [11980673.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):99-107 [16432833.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6915-35 [12362274.001]
  • [Cites] Inflamm Bowel Dis. 2000 May;6(2):103-6 [10833069.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22322-9 [9268383.001]
  • [Cites] Blood. 2000 May 15;95(10):3208-13 [10807790.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6116-33 [11085536.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7782-9 [16140946.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2969-76 [15126327.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):615-26 [12555074.001]
  • [Cites] Histol Histopathol. 2003 Apr;18(2):665-77 [12647816.001]
  • [Cites] J Cell Biochem. 2005 Jan 1;94(1):5-24 [15514923.001]
  • [Cites] Anal Biochem. 2005 Aug 15;343(2):347-9 [15992761.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3730-40 [10446989.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3207-13 [12036935.001]
  • [Cites] Int J Cancer. 2005 Jul 10;115(5):684-9 [15704097.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):870-7 [10702795.001]
  • (PMID = 18038152.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] United States / PHS HHS / / P50C A90388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / RBM5 protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


42. Beretta G, Furlanetto S, Regazzoni L, Zarrella M, Facino RM: Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies. J Pharm Biomed Anal; 2008 Nov 4;48(3):606-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNE is the most abundant and genotoxic product of oxidation of dietary polyunsaturated fatty acids, and is believed to be involved in the early stage of colorectal carcinogenesis on account of its genotoxic potential.
  • These results suggest that EGCG and green tea extract, beside the proposed mechanisms of chemoprevention that target multiple cell-signaling pathways that control cell proliferation and apoptosis in cancer cells, can also prevent protein carbonylation in the tumor tissue environment, depending on the pH of the medium surrounding the tissue, the type of tumor, the stage of dysregulation of lipid peroxidation and, finally, the stage of carcinoma development.

  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619756.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea
  •  go-up   go-down


43. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • CONCLUSIONS: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic cancer progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


44. Maw MK, Fujimoto J, Tamaya T: Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer; 2008 Nov 18;99(10):1557-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ID-1 histoscores and mRNA levels both significantly (P<0.05) increased in uterine cervical cancers according to clinical stage regardless of histopathological type or lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Inhibitor of Differentiation Protein 1 / biosynthesis. Neovascularization, Pathologic / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23 [14555767.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1198-203 [15026801.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7317-27 [9372963.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4577-88 [9671467.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):968-76 [10022839.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):933-8 [16189525.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):186-9 [16595146.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):592-8 [11034201.001]
  • [Cites] J Cell Sci. 2000 Nov;113 ( Pt 22):3897-905 [11058077.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5929-33 [11085505.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5703-6 [11479201.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6008-11 [11507043.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1812-22 [11896613.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Mol Carcinog. 2002 Sep;35(1):42-9 [12203366.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):677-82 [12640673.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4498-508 [12881706.001]
  • [Cites] J Pathol. 2003 Aug;200(5):561-7 [12898591.001]
  • [ErratumIn] Br J Cancer. 2009 Jul 21;101(2):377-8
  • (PMID = 19002177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Modulating Agents; 0 / Biomarkers, Tumor; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2584935
  •  go-up   go-down


45. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Zheng W, Armes JE, Slavin J, Zhu Y, Ni C: Preliminary comparison of tumor biologic factors in breast carcinomas from Australian and Chinese women. Anal Quant Cytol Histol; 2010 Jun;32(3):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Three hundred cases of breast carcinomas were assessed for histologic and immunophenotypic characteristics from the pathology archives of the Changhai and St. Vincent's Hospitals.
  • CONCLUSION: This study indicates that both inherent tumor biology and stage at presentation influence adversely affect the outcome of breast carcinoma in Chinese compared as with Australian women.


47. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA: Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1064-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
  • PURPOSE: Intensity-modulated radiation treatment (IMRT) is increasingly used in the treatment of squamous cell carcinoma of the anal canal (SCCAC).
  • In patients with advanced tumor or nodal stage, common iliac nodes should also be included in the CTV.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20350793.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP: Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis; 2010 Jan;31(4):599-610
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis.
  • Ovarian cancer is the fifth leading cause of cancer death for women in the US, yet survival rates are over 90% when it is diagnosed at an early stage, highlighting the need for biomarkers for early detection.
  • To enhance the discovery of tumor-specific proteins that could represent novel serum biomarkers for ovarian cancer, we depleted serum of highly abundant proteins which can mask the detection of proteins present in serum at low concentrations.
  • Three commercial immunoaffinity columns were used in parallel to deplete the highly abundant proteins in serum from 60 patients with serous ovarian carcinoma and 60 non-cancer controls.
  • The number of protein spots that were elevated in ovarian cancer sera by at least twofold ranged from 36 to 248, depending upon the depletion and separation methods.
  • From the 33 spots picked for MS analysis, nine different proteins were identified, including the novel candidate ovarian cancer biomarkers leucine-rich alpha2 glycoprotein-1 and ficolin 3.
  • Western blotting validated the relative increases in serum protein levels for three of the proteins identified, demonstrating the utility of this approach for the identification of novel serum biomarkers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 2002 Sep;23(18):3168-81 [12298089.001]
  • [Cites] Anal Chem. 2002 Apr 15;74(8):1779-91 [11985308.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):129-40 [15199385.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2476-95 [15274142.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Obstet Gynecol. 1971 Sep;38(3):427-35 [4999312.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Int J Cancer. 1988 Nov 15;42(5):677-80 [3182103.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Electrophoresis. 1996 Mar;17(3):612-6 [8740187.001]
  • [Cites] Crit Rev Immunol. 1995;15(3-4):201-14 [8834448.001]
  • [Cites] Arch Biochem Biophys. 1998 Dec 15;360(2):223-32 [9851834.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1933-45 [16099937.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1742-51 [16212428.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4625-36 [16220531.001]
  • [Cites] Proteomics. 2006 Jun;6(11):3236-42 [16645986.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1379-87 [16739989.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3938-48 [16767791.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2167-74 [16854842.001]
  • [Cites] J Proteome Res. 2006 Dec;5(12):3318-25 [17137333.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):64-71 [17030953.001]
  • [Cites] Neoplasia. 2007 Jan;9(1):1-7 [17325738.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1440-50 [17315909.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):257-67 [17303479.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Electrophoresis. 2007 Dec;28(23):4302-10 [18041032.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):339-51 [18076136.001]
  • [Cites] Mol Immunol. 2008 Mar;45(6):1623-32 [18006063.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Immunol Methods. 2008 Jul 20;336(1):22-9 [18436231.001]
  • [Cites] PLoS One. 2008;3(6):e2425 [18560578.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):591-9 [17944921.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] Fertil Steril. 2008 Sep;90(3):761-8 [17583700.001]
  • [Cites] PLoS Med. 2008 Dec 2;5(12):e232 [19053170.001]
  • [Cites] Arch Gynecol Obstet. 2009 Mar;279(3):365-71 [18665377.001]
  • [Cites] J Proteome Res. 2009 Feb;8(2):942-57 [19093873.001]
  • [Cites] Crit Rev Clin Lab Sci. 2007;44(1):87-114 [17175521.001]
  • [Cites] Cancer Treat Res. 2002;107:61-97 [11775462.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • (PMID = 20162585.001).
  • [ISSN] 1522-2683
  • [Journal-full-title] Electrophoresis
  • [ISO-abbreviation] Electrophoresis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-04; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-04; United States / NCI NIH HHS / CA / R01CA106878; United States / PHS HHS / / RRR15808
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / IgY; 0 / Immunoglobulins
  • [Other-IDs] NLM/ NIHMS264126; NLM/ PMC3520508
  •  go-up   go-down


49. Brunner A, Schönhuber G, Waldner M, Schaefer G, Mikuz G, Verdorfer I: Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. Anal Quant Cytol Histol; 2008 Oct;30(5):297-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system.
  • OBJECTIVE: To evaluate differences in chromosomal aberrations in recurrent urothelial cancer (UC) of the bladder between the World Health Organization (WHO) 1973 and 2004 classification a retrospective study was performed.
  • Grade 2 tumors, reclassified as high-grade tumors, were of higher stage and showed aberrations usually associated with higher grade and poor outcome (1p+, 16p+, -2 and -5q).

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980162.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol; 2006;1:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
  • PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
  • 10 TNM-stage and age matched HIV-seronegative patients (1992-2003) were compared with the 10 HIV-seropositive patients.
  • Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Anus Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods


51. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol; 2008 Sep;3(9):1018-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
  • INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1416-24 [18165618.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2677-85 [10870049.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2690-5 [10914711.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):904-12 [11895925.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Clin Pharmacol Ther. 1985 Aug;38(2):228-34 [4017423.001]
  • [Cites] Clin Pharmacol Ther. 1985 Oct;38(4):387-93 [4042521.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20 [8833984.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):301-3 [9135505.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):32-43 [17242669.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):933-8 [17909356.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • (PMID = 18758305.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS52764; NLM/ PMC2562273
  •  go-up   go-down


52. Alvarez G, Perry A, Tan BR, Wang HL: Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol; 2006 Jul;19(7):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification.
  • The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated.
  • In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers.
  • There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times.
  • These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification.
  • [MeSH-major] Anus Neoplasms / metabolism. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648870.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


53. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • METHODS: Patients with locally invasive (T2-4) primary or node-positive rectal cancer located <12 cm from the anal verge were recruited for this pilot study.
  • Pretreatment tumor size and stage were determined by endorectal ultrasonography, CT, and magnetic resonance imaging.
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


54. Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH, Zhong D, Zhou W: Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Res; 2005;7(6):R1051-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer.
  • INTRODUCTION: Identification of breast cancer patients at risk for postoperative distant relapse is an important clinical issue.
  • METHODS: Using 'counting alleles', a novel experimental method, we determined allelic status of chromosomes 8p and 18q in a case-control study with 65 early stage, node negative, invasive ductal carcinomas (IDCs).
  • CONCLUSION: Our finding suggests that differential allelic loss of chromosomes 8p and 18q may represent subtypes of early stage IDC with different tumor progression behaviors.
  • [MeSH-major] Allelic Imbalance. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 8 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 31;415(6871):484-5 [11831227.001]
  • [Cites] Lancet. 2002 Jan 19;359(9302):219-25 [11812558.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3863-9 [12473601.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):50-4 [12490761.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Prostate. 2004 Sep 15;61(1):81-91 [15287096.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Nat Biotechnol. 1998 Jan;16(1):49-53 [9447593.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1031-6 [9615760.001]
  • [Cites] Nat Biotechnol. 1996 Mar;14(3):303-8 [9630890.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):151-6 [10084107.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):854-7 [10706093.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):305-10 [10861509.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):78-81 [11135558.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] J Pathol. 2001 Apr;193(4):442-9 [11276002.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):65-72 [11790983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13647-52 [12370419.001]
  • (PMID = 16457686.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1410773
  •  go-up   go-down


55. Lunny DP, Weed E, Nolan PM, Marquardt A, Augustin M, Porter RM: Mutations in gasdermin 3 cause aberrant differentiation of the hair follicle and sebaceous gland. J Invest Dermatol; 2005 Mar;124(3):615-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Defolliculated (Dfl) is a spontaneous mouse mutant with a hair-loss phenotype that includes altered sebaceous gland differentiation, short hair shafts, aberrant catagen stage of the hair cycle, and eventual loss of the hair follicle.
  • Immunohistochemical analysis revealed that gasdermins are expressed specifically in cells at advanced stages of differentiation in the upper epidermis, the differentiating inner root sheath and hair shaft and in the most mature sebocytes of the sebaceous gland and preputial, meibomium, ceruminous gland, and anal glands.
  • [MeSH-minor] Animals. Antibodies. Antibody Specificity. Base Sequence. Carcinoma, Squamous Cell. Cell Differentiation. Cell Line, Tumor. Humans. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Mutant Strains. Molecular Sequence Data. Phenotype. Skin Neoplasms


56. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • Early stage disease, low T-score and absence of infiltration in adjacent organs were associated with a reduced need for colostomy in univariate analysis.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Hauerstock D, Ennis RD, Grossbard M, Evans A: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer; 2010 Oct;9(4):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  • PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell carcinoma of the anal canal in HIV-positive patients treated at a single institution.
  • PATIENTS AND METHODS: HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries.
  • We reviewed hospital and treatment charts to gather data relating to demographics, HIV status including cluster of differentiation 4 (CD4) count and viral load, tumor stage, radiation and chemotherapy treatment, toxicity and local control, and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal


59. Chen Y, Lim BK, Hashim OH: Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. J Hematol Oncol; 2009;2:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.
  • BACKGROUND: The general enhanced expression of alpha1-antichymotrypsin (ACT), clusterin (CLU), alpha1-antitrypsin (AAT), haptoglobin beta-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported.
  • In the present study, we compared the expression of the serum acute-phase proteins (APPs) in the patients according to their stages of cancer.
  • RESULTS: Different altered stage correlative expression of the high abundance serum APPs was demonstrated in sera of the patients studied.
  • While the expression of ACT, HAP and AAT appeared to demonstrate positive correlation with the three initial stages of the cancer, inverse correlation was apparently detected in the expression of LRG and CLU.
  • For patients who were diagnosed with stage IV of the cancer, expression of the serum APPs did not conform to the altered progression changes.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Carcinoma in Situ / blood. Ovarian Neoplasms / blood


60. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol; 2008 Mar;108(3):619-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate receptor alpha as a tumor target in epithelial ovarian cancer.
  • FRalpha staining was analyzed in light of disease morphology, stage, grade, debulking status, and time from diagnosis to recurrence and death.
  • CONCLUSION: FRalpha expression occurs frequently, especially in the common high-grade, high-stage serous tumors that are most likely to recur.
  • New findings from this study show that FRalpha expression is maintained on metastatic foci and recurrent tumors, suggesting that novel folate-targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2003 May;44(5):700-7 [12732670.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):52-7 [17582475.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1085-97 [15094208.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1219-31 [15094217.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Aug;287(2):C517-26 [15102609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6 [2062838.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5329-38 [1717147.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3396-401 [1596899.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5791-6 [8242637.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] Int J Cancer Suppl. 1994;8:89-95 [8194901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61 [7568072.001]
  • [Cites] APMIS. 1995 Sep;103(9):663-70 [7488388.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):121-6 [9583724.001]
  • [Cites] Arch Biochem Biophys. 1999 Jun 15;366(2):183-91 [10356282.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1505-12 [15634643.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Curr Pharm Biotechnol. 2005 Apr;6(2):131-50 [15853692.001]
  • [Cites] J Pharm Sci. 2005 Oct;94(10):2135-46 [16136558.001]
  • [Cites] Front Biosci. 2006;11:506-19 [16146749.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2168-72 [16172227.001]
  • [Cites] Curr Oncol Rep. 2005 Nov;7(6):451-8 [16221382.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Feb;21(1):49-60 [16480331.001]
  • [Cites] Cancer. 2006 May 1;106(9):1933-9 [16572412.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36 [16331500.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):603-9 [16704197.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1994-2004 [16767218.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1007-16 [16763819.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4254-61 [16908932.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8 [17062694.001]
  • [Cites] Cancer Immun. 2007;7:6 [17346028.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):141-52 [17333345.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2557-67 [17473184.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):938-42 [17487842.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1585-92 [17551919.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Gene Ther. 2003 Jun;10(12):1018-25 [12776159.001]
  • (PMID = 18222534.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA80628; United States / NCI NIH HHS / CA / K12 CA090628-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS123756; NLM/ PMC2707764
  •  go-up   go-down


61. Zuo ZG, Song HY, Xu C, Li J, Ni SC, Chen SQ: [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors]. Zhonghua Wai Ke Za Zhi; 2009 Jul 1;47(13):988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors].
  • OBJECTIVE: To study the combination of trans-anal intersphincteric resection and transabdominal total mesorectal excision for anus-retained ultra-low rectal tumors.
  • METHODS: Clinical data of 34 ultra-low rectal tumor patients without external anal sphincter involved, who underwent the combination surgery, were retrospectively analyzed.
  • For pathological types, there were 23 cases of adenocarcinoma (9 well differentiated and 14 moderately differentiated), 1 papillary carcinoma, 2 rectal stromal tumor, 5 rectal villous adenoma with neoplasia and 3 giant villous adenoma.
  • For pathological stages, there were 18 cases at stage pTNM I, 5 at IIA, 1 at IIB, 4 at IIIA, 1 at III and for T grading, there were 15 cases at stage T1, 5 at T2, 8 at T3, 1 at T4.
  • Because of the dysfunction of bowel control, bowel frequency varied from 3 to 12 in the early stage after operation, but with the recovery of anus function, bowel frequency decreased and ranged form 1 to 5 times a day and the time of formed bowel control could be more than 5 min in 6-12 months after operation.
  • However, patients underwent total resection of internal anal sphincter still suffered from incontinence of loose stool after 1 year.
  • CONCLUSION: The combination of trans-anal ISR and trans-abdominal TME for anus-retained ultra low rectal tumor is not only coincident with radical tumor principle but also retains the function of anus, on the premise of the strict indication.
  • [MeSH-major] Anal Canal / surgery. Mesentery / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957808.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early stage tumours should be explored.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal Canal. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Revuz J: Hidradenitis suppurativa. J Eur Acad Dermatol Venereol; 2009 Sep;23(9):985-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Axillary and inguinal involvement is more common in females; peri-anal and buttocks localizations are prevalent in males.
  • The main complications are arthropathy, carcinoma.
  • Treatment depends upon the stage of the disease.
  • Early nodular lesions may be treated by antibiotics for acute stage; long-term antibiotics, zinc salts may be useful as maintenance treatment; anti-TNF drugs have been used in severe cases; systemic steroids, estrogens, anti-androgens, retinoids have been used as options with limited success.

  • Genetic Alliance. consumer health - Hidradenitis Suppurativa.
  • Genetics Home Reference. consumer health - hidradenitis suppurativa.
  • MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682181.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


64. Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol; 2007 Jun;20(6):656-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.
  • When cancer was present in areas of chronic pancreatitis, this altered expression of alpha6beta4 integrin identified the cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415382.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21-CA102125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alpha6beta4
  • [Other-IDs] NLM/ NIHMS517144; NLM/ PMC4697742
  •  go-up   go-down


65. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


66. Oehler-Jänne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, Bonet M, Allal AS, Ciernik IF: HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol; 2008 May 20;26(15):2550-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
  • PURPOSE: To define clinical outcome after definitive chemoradiotherapy (CRT) of anal carcinoma in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
  • Local disease control (LC), relapse-free survival (RFS), overall survival (OS), cancer-specific survival (CSS), toxicity, and prognostic factors were investigated.
  • RESULTS: HIV-positive patients were younger (mean age, 48 v 62 years; P < .0005), predominantly male (93% v 25%; P < .0005), and with early-stage (P = .06) and large-cell histology (90% v 67%; P = .005) disease.
  • CONCLUSION: Long-term LC and acute toxicity represent major clinical challenges in HIV-positive patients with anal carcinoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy


67. Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS: Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A; 2008 Jul 22;105(29):10155-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BAC), a subtype of lung adenocarcinoma (ADC) without stromal, vascular, or pleural invasion, is considered an in situ tumor with a 100% survival rate.
  • Correlative gene expression analyses demonstrated a high percentage of them to be poor prognosis markers in early stage ADC.
  • Quantitative PCR also validated the amplification and overexpression of PDCD6 and TERT on chromosome 5p and the prognostic significance of PDCD6 in early stage ADC patients.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 26;288(2):420-6 [11606059.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):207-8 [11836235.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 15;291(5):1166-72 [11883939.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4094-100 [12024023.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7 [12440623.001]
  • [Cites] Biochim Biophys Acta. 2002 Nov 4;1600(1-2):68-73 [12445461.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Mar;23(3):409-14 [12614815.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):81-9 [12819013.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1936-47 [12932674.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 9;5:13 [15040819.001]
  • [Cites] Bioessays. 2004 Nov;26(11):1164-74 [15499579.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Science. 1996 Jan 26;271(5248):521-5 [8560270.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Biochem J. 1997 Dec 1;328 ( Pt 2):718-20 [9441591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5211-6 [9560255.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1533-40 [9880530.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1090-6 [15564434.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3636-7 [15201182.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Biotechnol Lett. 2005 Jul;27(14):1011-5 [16132846.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6177-85 [16144918.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):11-9 [16130125.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1452-9 [16641908.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):79-94 [17251915.001]
  • [Cites] Anal Cell Pathol. 2001;22(3):111-21 [11455030.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Jan;121(1):42-7 [11135158.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14053-8 [11278427.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4677-82 [11076956.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):839-43 [11533664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • (PMID = 18632575.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE11945
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / PDCD6 protein, human; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2465804
  •  go-up   go-down


68. Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, Freeman A, Wollenschlaeger A, Ralph DJ, Stoeber K, Williams GH: DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res; 2009 Dec 01;15(23):7335-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.
  • We have analyzed replication licensing factors (RLF), together with DNA ploidy status, to investigate their role in progression of penile squamous cell carcinoma and to assess their utility as novel prognostic tools.
  • Accelerated cell cycle progression was linked to increasing tumor size, stage, and depth of invasion.
  • Our results also identify the DNA replication initiation pathway as a potentially attractive therapeutic target in penile squamous cell carcinoma.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Carcinoma / therapy. Gene Expression Regulation, Neoplastic. Penile Neoplasms / genetics. Penile Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] IARC Sci Publ. 1992;(120):45-173 [1284606.001]
  • [Cites] J Urol. 1993 Mar;149(3):492-7 [8437253.001]
  • [Cites] Nat Chem Biol. 2008 Jun;4(6):331-2 [18488006.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1128-34 [19293805.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] J Urol. 2006 May;175(5):1700-4; discussion 1704-5 [16600735.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):119-27 [17160531.001]
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Br J Urol. 1993 Dec;72(6):941-5 [8306161.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):755-61 [9630184.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2417-25 [19318489.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):735-41 [16915294.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6153-61 [17947481.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):672-9 [18032010.001]
  • [Cites] J Urol. 2006 Jun;175(6):2103-8; discussion 2108 [16697813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Exp Cell Res. 2007 Oct 15;313(17):3789-99 [17689530.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):799-806 [18756287.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Annu Rev Biochem. 2002;71:333-74 [12045100.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):487-95 [18425779.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1384-93 [17406359.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):217-26 [12612656.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2855-64 [18843031.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Aug;29(4):185-98 [17879626.001]
  • [Cites] Ann Surg. 1921 Feb;73(2):141-60 [17864409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1548-54 [18414413.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • (PMID = 19920109.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6263
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2788529; NLM/ UKMS27727
  •  go-up   go-down


69. Wortham M, He L, Gyamfi M, Copple BL, Wan YJ: The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig Dis Sci; 2008 Oct;53(10):2761-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By mechanisms that are not completely understood, this disease may progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
  • The occurrence of SAMe depletion at this early, benign stage of NASH development in db/db mice with fatty liver suggests that SAMe supplementation may be (A) targeted to individuals susceptible to NASH (i.e., NAFLD patients) and (B) preventative of NASH before substantial liver injury has occurred.

  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1310-5 [7557886.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):767-76 [17710550.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1090-7 [8903381.001]
  • [Cites] Pharmacol Ther. 1997;73(3):265-80 [9175157.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):G14-21 [9655679.001]
  • [Cites] Hepatology. 1999 May;29(5):1471-8 [10216131.001]
  • [Cites] J Hepatol. 1999 Jun;30(6):1081-9 [10406187.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] PLoS Biol. 2005 Apr;3(4):e101 [15760270.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] J Biochem Mol Toxicol. 2006;20(1):39-47 [16498637.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):615-22 [16511594.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1067-75 [10772651.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Jul;279(1):G178-85 [10898761.001]
  • [Cites] J Hepatol. 2000 Dec;33(6):907-14 [11131452.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5560-5 [11320206.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):679-90 [12406439.001]
  • [Cites] Semin Liver Dis. 2004 Feb;24(1):3-20 [15085483.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1035-43 [15256362.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem Pharmacol. 1978 May 15;27(10):1431-3 [697884.001]
  • [Cites] FEBS Lett. 1982 Aug 23;145(2):293-7 [7128827.001]
  • [Cites] Hepatology. 1988 Jan-Feb;8(1):65-8 [3338721.001]
  • [Cites] Scand J Gastroenterol. 1989 May;24(4):407-15 [2781235.001]
  • [Cites] Hepatology. 1990 Feb;11(2):165-72 [2307395.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Hepatology. 1992 Feb;15(2):297-301 [1735533.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):4979-86 [1516054.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] Hepatology. 1995 Jan;21(1):207-14 [7806156.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Dec 30;205(3):1748-54 [7811261.001]
  • [Cites] Int J Mol Med. 2006 Sep;18(3):433-9 [16865227.001]
  • [Cites] J Lipid Res. 2006 Oct;47(10):2280-90 [16829692.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5223-8 [17360356.001]
  • [Cites] Hepatology. 2007 May;45(5):1306-12 [17464973.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1366-74 [17476695.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):632-5 [8628397.001]
  • (PMID = 18299981.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA53596; United States / NIAAA NIH HHS / AA / R01 AA014147; United States / NCRR NIH HHS / RR / P20 RR021940; United States / NIAAA NIH HHS / AA / AA14147; United States / NCI NIH HHS / CA / R01 CA053596
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; AE28F7PNPL / Methionine; GAN16C9B8O / Glutathione; N91BDP6H0X / Choline
  • [Other-IDs] NLM/ NIHMS565666; NLM/ PMC3991247
  •  go-up   go-down


70. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality


71. Costa AF, Altemani A, Vékony H, Bloemena E, Fresno F, Suárez C, Llorente JL, Hermsen M: Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type. Anal Cell Pathol (Amst); 2010;33(5):217-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: genome-wide DNA copy number changes were analyzed by microarray CGH in ACC-HGT, 4 with transformation into moderately differentiated adenocarcinoma (MDA) and two into poorly differentiated carcinoma (PDC), 5 solid ACC.
  • CONCLUSION: ACC-HGT may not necessarily reflect a more advanced stage of tumor progression, but rather a transformation to another histological form in which the poorly differentiated forms (PDC) presents a genetic complexity similar to the solid ACC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / pathology. Cell Transformation, Neoplastic / pathology. Gene Expression Profiling

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20978318.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC4605554
  •  go-up   go-down


72. Engin G: Endosonographic imaging of anorectal diseases. J Ultrasound Med; 2006 Jan;25(1):57-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Rectal carcinoma appears on endorectal sonography as a low-echogenicity lesion that abruptly interrupts the normal sequence of layers.
  • The internal anal sphincter is seen very clearly on endoanal sonography, and it is easy to appreciate atrophy and small tears of this sphincter.
  • Endoanal sonography cannot accurately show thinning of the external anal sphincter.
  • CONCLUSIONS: Endosonography can accurately stage primary rectal tumors and assess the internal anal sphincter.
  • However, magnetic resonance imaging can be used a complementary modality to endosonography, especially for evaluation of external anal sphincter atrophy and deep pelvic inflammation.
  • [MeSH-major] Anus Diseases / ultrasonography. Endosonography / methods. Rectal Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371556.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


73. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB: Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One; 2009;4(5):e5583
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
  • Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer.
  • However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.
  • METHODOLOGY AND PRINCIPAL FINDINGS: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment.
  • The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma.
  • Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis.
  • They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased.
  • Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma.
  • Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
  • CONCLUSIONS: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • [Cites] Mol Oncol. 2008 Jun;2(1):54-69 [19081821.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2929-40 [14988385.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]
  • [Cites] Arterioscler Thromb. 1993 Nov;13(11):1662-7 [8218108.001]
  • [Cites] Biochem J. 1998 Mar 15;330 ( Pt 3):1107-14 [9494074.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):364-8 [9887232.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2740-8 [16510595.001]
  • [Cites] Matrix Biol. 2006 May;25(4):223-31 [16503403.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2846-54 [16996261.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11 [17346539.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):928-37 [17509990.001]
  • [Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]
  • [Cites] Hum Pathol. 2008 May;39(5):747-57 [18439941.001]
  • [Cites] Adv Exp Med Biol. 2008;617:23-40 [18497028.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1781(9):547-57 [18501205.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • (PMID = 19440550.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Lysophospholipids; 0 / Membrane Proteins; 22002-87-5 / lysophosphatidic acid
  • [Other-IDs] NLM/ PMC2679144
  •  go-up   go-down


74. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting cancer at an earlier stage.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • SA with apocrine metaplasia, i.e. apocrine adenosis (AA), presents with a higher degree of atypical apocrine hyperplasia, and these lesions are believed to be precursors of apocrine carcinoma, in situ and invasive.